title: Cutaneous malignant melanoma and Parkinson disease: Common pathways?
abstract: The mechanisms underlying the high prevalence of cutaneous malignant melanoma (CMM) in Parkinson disease (PD) are unclear, but plausibly involve common pathways. 129Ser-phosphorylated α-synuclein, a pathological PD hallmark, is abundantly expressed in CMM, but not in normal skin. In inherited PD, PARK genes harbor germline mutations; the same genes are somatically mutated in CMM, or their encoded proteins are involved in melanomagenesis. Conversely, genes associated with CMM affect PD risk. PD/CMM-targeted cells share neural crest origin and melanogenesis capability. Pigmentation gene variants may underlie their susceptibility. We review putative genetic intersections that may be suggestive of shared pathways in neurodegeneration/melanomagenesis. Ann Neurol 2016;80:811-820.
authors.affiliation: Department of Neurology and Neurosurgery, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv.|Center of Advanced Technologies in Rehabilitation, Sheba Medical Center, Tel Hashomer.
authors.forename: Rivka
authors.initials: R
authors.lastname: Inzelberg
authors.affiliation: Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv.
authors.forename: Shira
authors.initials: S
authors.lastname: Flash
authors.affiliation: Susanne Levy Gertner Oncogenetics Unit, Institute of Human Genetics, Sheba Medical Center, Tel Hashomer.|Departments of Internal Medicine and Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv.
authors.forename: Eitan
authors.initials: E
authors.lastname: Friedman
authors.affiliation: Department of Dermatology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
authors.forename: Esther
authors.initials: E
authors.lastname: Azizi
mesh_terms: D019941:Cyclin-Dependent Kinase Inhibitor p16; D050763:Cyclin-Dependent Kinase Inhibitor p18 / Q000235:genetics; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D008545:Melanoma / Q000150:complications* / Q000235:genetics*; D010300:Parkinson Disease / Q000150:complications* / Q000235:genetics*; D000070579:Parkinson Disease Associated Proteins / Q000235:genetics; D020641:Polymorphism, Single Nucleotide; D044102:Receptor, Melanocortin, Type 1 / Q000235:genetics; D016194:Receptors, N-Methyl-D-Aspartate / Q000235:genetics; D012878:Skin Neoplasms / Q000150:complications* / Q000235:genetics*; D051844:alpha-Synuclein / Q000235:genetics; D000096142:Cutaneous Malignant Melanoma
chemical_list: D019941:Cyclin-Dependent Kinase Inhibitor p16; D050763:Cyclin-Dependent Kinase Inhibitor p18; D000070579:Parkinson Disease Associated Proteins; D044102:Receptor, Melanocortin, Type 1; D016194:Receptors, N-Methyl-D-Aspartate; D051844:alpha-Synuclein; C000614131:CDKN2A protein, human